Pharma

Closed Loop Medicine Brings Personalised GLP-1 Dosing to the U.S with WeDosify

UK start-up's new platform promises to cut GLP-1 discontinuation rates by tailoring dose escalation to each patient's response.

Vedanta’s Live Bacteria Cocktail Fails Phase 2 Ulcerative Colitis Trial

While VE202 misses efficacy endpoint, strong safety profile underscores potential of microbiome-based therapies; company doubles down on Phase 3 trial in recurrent C. difficile.

Eli Lilly's Oral GLP-1 Candidate Orforglipron Shows 12% Weight Loss in Pivotal Trial, Eyes Regulatory Filing

Phase 3 data show modest efficacy for Lilly's once-daily oral GLP-1, positioning it as a convenient but less potent rival to injectable obesity drugs.

Antibodies.com Supercharges UK Operations with Move to Larger Cambridge HQ

Antibodies.com has moved to a new, five-times-larger headquarters at Cambridge Technopark to support rapid growth and better serve life science researchers worldwide.

Compass Pathways' Phase 3 Psilocybin Readout Raises Efficacy Questions Despite Meeting Primary Endpoint

Investor skepticism underscores challenges in demonstrating robust clinical value in psychedelic therapeutics for depression.

Novo Nordisk Strikes $812 Million Deal with Deep Apple Therapeutics to Strengthen Obesity Pipeline

The Wegovy maker announces strategic agreement worth up to $812 million with Deep Apple Therapeutics, continuing their aggressive investment into its obesity drug pipeline.